ArticleJournal of movement disorders2026
Serum Neuronal Extracellular Vesicles for RT-QuIC Assays to Detect Pathological α-Synuclein in Synucleinopathies.
Article in Journal of movement disorders, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
objectivePathological α-synuclein aggregation is a key finding in synucleinopathies, including Parkinson's disease (PD), dementia with Lewy bodies, and multiple system atrophy. The real-time quaking-induced conversion (RT-QuIC) assay using cerebrospinal fluid (CSF) can sensitively detect pathological α-synuclein aggregates and is supported by a strong biological rationale. However, the invasive nature of CSF collection limits its clinical utility. A blood-based RT-QuIC assay is therefore of growing interest; although evidence remains limited, it has shown good performance in distinguishing patients with PD from healthy controls (HCs). In this study we investigated pathological α-synuclein aggregates in the neuron-derived extracellular vesicles (nEVs) isolated from serum samples of patients with synucleinopathies and HCs.
methodsSerum samples were collected from patients diagnosed with synucleinopathies and HCs without neurological disorders. Total extracellular vesicles (EVs) were isolated from serum using an ExoQuick kit, after which nEVs were isolated via L1-cell adhesion molecule immunocapture. The identity of the nEVs was confirmed by transmission electron microscopy (TEM), nanoparticle tracking analysis (NTA), and western blotting. Pathological α-synuclein aggregates in EVs were assessed by western blotting, dot blotting, and RT-QuIC assays.
resultsThe concentration and abundance of EVs were comparable between the PD and HC groups. TEM and NTA confirmed EV morphology and size distribution, and western blotting validated the neuronal quality of the nEVs. Compared with those from HCs, nEVs from patients with synucleinopathies showed higher levels of phosphorylated or aggregated α-synuclein. Optimized RT-QuIC conditions using nEV enabled preliminary discrimination of synucleinopathy from HC with nEVs, with distinct kinetic profiles observed between groups.
conclusionSerum-derived nEVs represent a promising, minimally invasive seed source for RT-QuIC assays, offering robust diagnostic performance for the detection of synucleinopathies and potential applicability in broader clinical settings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.